Accurate testing that helps prevent the spread of global illnesses
BioMedomics is working hard to develop and commercialize tests for infectious diseases that affect populations all over the world. Our tests are designed to provide accurate and fast results for providers and clinical decision-makers.
BioMedomics has developed and launched one of the world’s first rapid point-of-care lateral flow immunoassays for the diagnosis of coronavirus infection. The test has been used widely around the globe to combat infections. This test detects both early marker and late marker, IgM/IgG antibodies in human finger-prick or venous blood samples.
BioMedomics has launched the SARS-CoV-2 Antigen Test Kit (LFIA) to aid in the diagnosis of an active coronavirus infection. The test detects the presence of the novel coronavirus antigens via nasopharyngeal and provides diagnostic results within 15 minutes via a rapid lateral flow immunoassay (LFIA).
BioMedomics expertise in antibody development allows us to develop novel diagnostic tests to assist clinicians in the diagnosis of infectious disease. From lateral flow to molecular platforms, BioMedomics is constantly looking to find solutions that benefit global populations.
Several pneumonia cases were discovered in late 2019, with clinical presentations resembling viral pneumonia. Pathogenic gene sequencing confirmed that the pathogen was a novel coronavirus, which was named 2019 novel coronavirus (SARS-CoV-2). Similar to previous outbreaks of coronavirus infection in humans, SARS-CoV-2 infection caused the novel corona virus disease (COVID-19) and the outbreak developed into an epidemic that quickly spread all over the world, resulting in public health emergencies around the world.